HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of metadherin sensitizes breast cancer cells to AZD6244.

Abstract
The development of systemic therapy drug resistance for breast cancer treatment is an ongoing problem, thus, so are the potential molecular mechanisms of it. AZD6244 is a novel ATP-uncompetitive inhibitor to MAP/ERK kinase (MEK) 1/2 which has been demonstrated to be potent, selective and safe in the clinical trials and previous studies. However, the precise role of resistance to AZD6244 is largely unknown. We and other groups have reported that the novel oncogene Metadherin (MTDH) is associated with multiple drug resistance, but there is no report about its role in treatment of AZD6244. Here we report that the resistance to AZD6244 can be reserved by downregulating MTDH in breast cancer cell lines. When the MTDH was downregulated, the breast cancer cells exhibited a significantly increased sensitivity to AZD6244 as measured by MTT assay. After treated with AZD6244 the MTDH-knockdown cells showed more apoptosis rate and growth inhibition. We also showed that knockdown of MTDH cannot only increase expression of FOXO3a but also activate it by promoting its translocation via MTDH/ERK1/2/FOXO3a pathway rather than MTDH/AKT/FOXO3a pathway. In conclusion knockdown MTDH can enhance the breast cancer cells sensitivity to AZD6244 via regulating the expression and activity of FOXO3a. These indicate us that MTDH is a candidate marker to predict the clinical efficacy of AZD6244 and targeting MTDH could overcome the resistance to AZD6244 in breast cancer cells.
AuthorsXiaoli Kong, Meena S Moran, Yuhan Zhao, Qifeng Yang
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 13 Issue 1 Pg. 43-9 (Jan 01 2012) ISSN: 1555-8576 [Electronic] United States
PMID22336587 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • AZD 6244
  • Benzimidazoles
  • Cell Adhesion Molecules
  • FOXO3 protein, human
  • Forkhead Box Protein O3
  • Forkhead Transcription Factors
  • MTDH protein, human
  • Membrane Proteins
  • RNA, Small Interfering
  • RNA-Binding Proteins
Topics
  • Apoptosis (drug effects)
  • Benzimidazoles (pharmacology)
  • Breast Neoplasms (genetics, metabolism, pathology, therapy)
  • Cell Adhesion Molecules (antagonists & inhibitors, genetics, metabolism)
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm
  • Female
  • Forkhead Box Protein O3
  • Forkhead Transcription Factors (biosynthesis, genetics)
  • Gene Knockdown Techniques
  • Humans
  • Membrane Proteins
  • RNA, Small Interfering (administration & dosage, genetics)
  • RNA-Binding Proteins
  • Transfection
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: